Athenex, Inc. (ATNX)

$0.1935

+0.01 (+4.03%)
Rating:
Recommendation:
Neutral
Symbol ATNX
Price $0.1935
Beta 1.221
Volume Avg. 4.05M
Market Cap 30.459M
Shares () -
52 Week Range 0.118-1.2
1y Target Est -
DCF Unlevered ATNX DCF ->
DCF Levered ATNX LDCF ->
ROE -551.65% Strong Sell
ROA -76.04% Strong Sell
Operating Margin -
Debt / Equity 889.97% Strong Buy
P/E -
P/B 1.09 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ATNX news


Dr. Johnson Lau
Healthcare
Drug Manufacturers—Specialty & Generic
NASDAQ Global Select

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.